Ariel Goitia, MD
Psychiatry · Cutler Bay, FLNPI 1679044523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alkermes, Inc. at 24.7% of the total. Reporting peaked in 2021 at $1,351 and has fallen 92.8% since, to $97 in 2025.
Across 145 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$689
- Indivior Inc.$500
- AbbVie$388
- Otsuka America Pharmaceutical, Inc.$331
- Teva Pharmaceuticals USA, Inc.$315
- Neurocrine Biosciences, Inc.$259
- plus $304 from 8 others
What the payments were for
- Speaking & faculty fees$191%
- Food & beverage$2,66996%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 35 | $689 |
| Indivior Inc. | 21 | $500 |
| AbbVie(2 entities) | 27 | $388 |
| Otsuka America Pharmaceutical, Inc. | 19 | $331 |
| Teva Pharmaceuticals USA, Inc. | 15 | $315 |
| Neurocrine Biosciences, Inc. | 11 | $259 |
| Johnson & Johnson | 6 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| UCB, Inc. | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Tempus AI, Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
How this compares
$2,787 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 126 | $6,434 |
| Mirtazapine | 419 | $4,586 |
| Escitalopram Oxalate | 495 | $3,422 |
| Aripiprazole | 49 | $3,033 |
| Sertraline Hcl | 437 | $1,484 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 23 | $1,230 |
| Olanzapine | 42 | $1,150 |
| Bupropion XlBupropion Hcl | 86 | $1,089 |
| Trazodone Hcl | 293 | $1,066 |
| Quetiapine Fumarate | 149 | $1,045 |
| Amitriptyline Hcl | 48 | $787 |
| Clonazepam | 274 | $759 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $711 |
| Alprazolam | 135 | $567 |
| Divalproex Sodium ErDivalproex Sodium | 20 | $534 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Cutler Bay
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.